+1-888-308-5802     
Industry Categories News Contact Us

Australia approves Merck’s patent for use of paired CRISPR nickases

Author : Paroma Bhattacharya | Published Date : 2018-08-17 

Merck, the leading pharmaceutical and life science firm, has reportedly announced that it has availed permission for the patent application of paired CRISPR nickases from the Australian Patent Office. Sources claim that Merck's CRISPR integration patent portfolio already boasts of patents granted in Europe, Australia, China, Canada, South Korea, Israel, and Singapore.

According to trusted reports Merck’s IP would be required by commercial organizations for CRISPR-based DNA insertion if the firm needs access to the right defect in the somatic cells of the patient undergoing gene therapy. Merck plans to license this patent soon for various fields.

As per the granted patent application, two CRISPR nickases are targeted to one gene target that act by slashing the opposite strands of the chromosome series to generate a bi-stranded break.

Seeking Alpha reports Udit Batra CEO, Life Science, Merck KGaA to have stated that the allowance for this new patent represents a commendable advancement in CRISPR-enabled therapeutics safety. The paired nickase CRISPR technology is particularly important for the research community that requires extremely accurate methods during the development of treatment methodologies for difficult-to-treat diseases, he further affirms.

For the uninitiated, Merck was the first company that incepted custom biomolecules for genome editing across the globe (TargeTron™ RNA-guided group II introns & CompoZr™ zinc finger nucleases), motivating the overall R&D community to adopt this technique.

According to sources, the Australian Patent Office has not only approved the patent application for paired nickases but has also declared the grant for Merck's CRISPR integration 2017 patent after four anonymously filed petitions were withdrawn.

For the record, Merck KGaA is also the first company of its kind to have manufactured arrayed CRISPR libraries that reportedly cover the whole genome, allowing for a faster cure as scientists can precisely analyze the root cause of the disease.

About Author

Paroma Bhattacharya

Paroma Bhattacharya

Paroma currently works as a content developer for AlgosOnline. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched content in diverse fields. Apart from being a compulsive reader she also loves to cook, paint and travel

She can be contacted at- [email protected] | https://twitter.com/paromab1

Related News

Hitachi signs MoU with NSW government to develop Western Sydney

Published Date: 2018-11-16         Author: Paroma Bhattacharya

Hitachi, Ltd., the Japanese conglomerate company recently announced the signing of a Memorandum of Understanding with the New South Wales (NSW) Government of Australia. The MoU is an illustration of Hitachi’s commitment to cooperate with NSW for the development of Western Sydney Aerotropolis a... Read More

BHP buys stake in SolGold copper project in Ecuador for $35 million

Published Date: 2018-09-07         Author: Paroma Bhattacharya

The leading mining company BHP has recently signed a deal with SolGold, the Australian gold and copper mining company to earn a 6.1% stake in the latter. The deal, in which BHP will be paying $35 million for the stakes, will ensure that BHP earns a share in the copper-gold project, Cascabel, Ecuador... Read More

SwRI’s AC2AT-II consortium to focus on engine emissions solutions

Published Date: 2018-09-07         Author: Paroma Bhattacharya

Southwest Research Institute, one of the largest nonprofit R&D organizations in the U.S. recently announced the commencement of the Advanced Combustion Catalyst and Aftertreatment Technologies II, that will be starting from 15 November 2018 with a meeting at the San Antonio headquarters of SwRI.... Read More

© 2018 Fractovia. All Rights Reserved